Pages that link to "Q37652874"
Jump to navigation
Jump to search
The following pages link to VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management (Q37652874):
Displaying 50 items.
- Preeclampsia 2012 (Q21285024) (← links)
- Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension (Q26826864) (← links)
- Drug-induced glomerular disease: attention required! (Q26829793) (← links)
- Incidence and management of ZIv-aflibercept related toxicities in colorectal cancer (Q26830219) (← links)
- Medical management of brain tumors and the sequelae of treatment (Q26992174) (← links)
- Drug-induced glomerular disease: direct cellular injury (Q27692666) (← links)
- Chronic VEGF blockade worsens glomerular injury in the remnant kidney model (Q28728129) (← links)
- Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors. (Q30417015) (← links)
- Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies (Q30426853) (← links)
- Acute podocyte vascular endothelial growth factor (VEGF-A) knockdown disrupts alphaVbeta3 integrin signaling in the glomerulus. (Q31074551) (← links)
- Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data. (Q31102468) (← links)
- Advances in our understanding of the pathogenesis of glomerular thrombotic microangiopathy (Q33392316) (← links)
- Shiga toxin pathogenesis: kidney complications and renal failure (Q33397541) (← links)
- Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy (Q33410553) (← links)
- Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial (Q33424566) (← links)
- Anti-VEGF-related thrombotic microangiopathy in a child presenting with nephrotic syndrome (Q33430382) (← links)
- Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors (Q33698419) (← links)
- Bevacizumab increases risk for severe proteinuria in cancer patients (Q34124173) (← links)
- Anti-VEGF Cancer Therapy in Nephrology Practice (Q34152125) (← links)
- Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure (Q34206601) (← links)
- Regorafenib for cancer (Q34274239) (← links)
- Incidence and risk of proteinuria with aflibercept in cancer patients: a meta-analysis (Q34445829) (← links)
- High Density Lipoprotein Nanoparticles Deliver RNAi to Endothelial Cells to Inhibit Angiogenesis. (Q34496687) (← links)
- Collapsing focal segmental glomerulosclerosis resulting from a single dose of zoledronate (Q34562160) (← links)
- Mechanism of kidney injury caused by bevacizumab in rats (Q35038600) (← links)
- Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study (Q35120723) (← links)
- Nephrotoxicity of recent anti-cancer agents (Q35310741) (← links)
- Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center (Q36150811) (← links)
- Clinicopathological and prognostic factors for long-term survival in Chinese patients with metastatic renal cell carcinoma treated with sorafenib: a single-center retrospective study (Q36546814) (← links)
- Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma (Q36825455) (← links)
- VEGF inhibition, hypertension, and renal toxicity (Q37103555) (← links)
- Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study (Q37492128) (← links)
- VEGF regulates local inhibitory complement proteins in the eye and kidney. (Q37545004) (← links)
- Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea (Q37598818) (← links)
- Immunopathogenesis of idiopathic nephrotic syndrome with relapse (Q37742644) (← links)
- Aflibercept (VEGF Trap): one more double-edged sword of anti-VEGF therapy for cancer? (Q37780015) (← links)
- Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies? (Q37799821) (← links)
- Vascular endothelial growth factors and receptors: Anti-angiogenic therapy in the treatment of cancer (Q37874750) (← links)
- Nitric oxide and adverse events of vascular endothelial growth factor inhibitors (Q37886172) (← links)
- Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: A phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma (Q37926019) (← links)
- Proteinuria and hypertension with tyrosine kinase inhibitors. (Q37928902) (← links)
- Safety Profile and Tolerability of Antiangiogenic Agents in Non–Small-Cell Lung Cancer (Q37953162) (← links)
- Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology (Q37967508) (← links)
- Protective measures against ultrafiltration failure in peritoneal dialysis patients (Q37970606) (← links)
- Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy (Q37979314) (← links)
- Management of sunitinib adverse events in renal cell carcinoma patients: the Asian experience (Q38004605) (← links)
- Chemotherapy-related cardiotoxicity (Q38088974) (← links)
- Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy (Q38101885) (← links)
- Biophysics of glomerular filtration (Q38110744) (← links)
- Arterial hypertension and cancer. (Q38115762) (← links)